Senior private markets executive and operator focusing on growth-stage technology and healthcare investments, with experience leading portfolio transformation, strategic M&A and capital markets execution. Matthew D. Copley brings cross-functional experience sourcing deals, driving operational improvements, and working with management teams to scale revenue and margins; known for active board involvement and structuring equity and debt financing to support expansion.
Senior private markets executive and operator focusing on growth-stage technology and healthcare investments, with experience leading portfolio transformation, strategic M&A and capital markets execution. Matthew D. Copley brings cross-functional experience sourcing deals, driving operational improvements, and working with management teams to scale revenue and margins; known for active board involvement and structuring equity and debt financing to support expansion.
Focuses on growth-stage technology and healthcare companies, prioritizing platform businesses with clear unit economics and scalable go-to-market models. Employs hands-on partnership with founders, combining operational playbooks, strategic M&A and tailored capital structures (equity and debt) to accelerate revenue and margin expansion. Investment decisions favor differentiated product-market fit, predictable recurring revenue, and governance arrangements enabling active board oversight. Balances growth orientation with disciplined downside protection—staging capital, performance-linked instruments and exit planning across three- to seven-year horizons.
Focuses on growth-stage technology and healthcare companies, prioritizing platform businesses with clear unit economics and scalable go-to-market models. Employs hands-on partnership with founders, combining operational playbooks, strategic M&A and tailored capital structures (equity and debt) to accelerate revenue and margin expansion. Investment decisions favor differentiated product-market fit, predictable recurring revenue, and governance arrangements enabling active board oversight. Balances growth orientation with disciplined downside protection—staging capital, performance-linked instruments and exit planning across three- to seven-year horizons.
| Trades 860 | Longs Won 562/860 65% | Profit Factor 7.72 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $201,645.39 |
| Average Win $73,859.28 | Best Trade (Mar 31) $2.76M | Sharpe Ratio -9.34 |
| Average Loss -$18,052.26 | Worst Trade (Jun 29) -$478,132 | Z-Score 2.94 (99.67%) |
| Commissions $0 | Avg. Trade Length 10m 1w 1d | Expectancy $42,010.86 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 9,524 | 8,571 | 7,619 | 6,667 | 5,714 | 4,762 | 3,810 | 2,857 | 1,905 | 952 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 2,135 | $497,455 | $650,982.85 | - | $153,527.85 | 30.86% | -1.087% |
ABBV AbbVie Inc. | 1,092 | $213,294.35 | $270,783.24 | - | $57,488.89 | 26.95% | 0.0 |
AEP American Electric Power Company, Inc. | 2,003 | $225,337.76 | $246,048.52 | - | $20,710.76 | 9.19% | 0.0 |
AGGH Simplify Aggregate Bond ETF | 128,942 | $2.6M | $2.56M | - | -$41,261.3 | -1.59% | 0.0 |
ALL Allstate Corporation | 1,111 | $226,521.18 | $299,603.37 | - | $73,082.19 | 32.26% | 0.0 |
AMD Advanced Micro Devices, Inc. | 779 | $452,529 | $365,787.24 | - | -$86,741.76 | -19.17% | 0.0 |
AMGN Amgen Inc. | 747 | $223,668.87 | $311,648.4 | - | $87,979.53 | 39.33% | 0.0 |
AMZN Amazon.com Inc | 2,738 | $520,519.75 | $745,475.26 | - | $224,955.51 | 43.22% | -2.093% |
APH Amphenol Corporation | 2,352 | $207,352.32 | $197,215.2 | - | -$10,137.12 | -4.89% | 0.0 |
ARE Alexandria Real Estate Equities, Inc. | 4,287 | $209,805.92 | $207,276.45 | - | -$2,529.47 | -1.21% | 0.0 |
ARW Arrow Electronics Inc. | 1,289 | $159,633.96 | $266,139.83 | - | $106,505.87 | 66.72% | +1.925% |
ASML ASML Holding N.V. New York Registry Shares | 179 | $191,504.94 | $322,089.02 | - | $130,584.08 | 68.19% | +3.802% |
AVDE Avantis International Equity ETF | 3,172 | $235,165.53 | $296,677.16 | - | $61,511.63 | 26.16% | 0.0 |
AVEM Avantis Emerging Markets Equity ETF | 2,343 | $160,589.17 | $215,251.41 | - | $54,662.24 | 34.04% | 0.0 |
AVGO Broadcom Inc. | 1,385 | $357,225.77 | $585,024 | - | $227,798.23 | 63.77% | 0.0 |
AZN AstraZeneca PLC American Depositary Shares | 1,419 | $279,854.95 | $225,266.25 | - | -$54,588.7 | -19.51% | -1.952% |
BAC Bank of America Corporation | 6,543 | $259,626.18 | $417,835.98 | - | $158,209.8 | 60.94% | 0.0 |
BIL SPDR Bloomberg 1-3 Month T-Bill ETF | 17,408 | $1.6M | $1.59M | - | -$3,340.27 | -0.21% | 0.0 |
BRK-B Berkshire Hathaway Inc. | 706 | $325,970.7 | $373,770.52 | - | $47,799.82 | 14.66% | 0.0 |
BUYW Main Buywrite ETF | 245,634 | $3.45M | $3.58M | - | $124,843.37 | 3.61% | 0.0 |